GAITHERSBURG, Md. - An FDA panel on Friday overcame the concerns of its members about safety and flaws in trial design and unanimously recommended approval of Gilead Sciences Inc.'s Vistide (cidofovir injection) as a treatment for cytomegalovirus (CMV) retinitis in patients with AIDS.

Vistide is the first nucleotide analog antiviral agent to be recommended for FDA approval.